In a filing, Enliven Therapeutics Inc revealed its CHIEF FINANCIAL OFFICER Hohl Benjamin unloaded Company’s shares for reported $66504.0 on Jul 28 ’25. In the deal valued at $20.46 per share,3,250 shares were sold. As a result of this transaction, Hohl Benjamin now holds 23,000 shares worth roughly $0.44 million.
Then, Hohl Benjamin bought 4,250 shares, generating $90,100 in total proceeds.
Before that, Lyssikatos Joseph P sold 12,500 shares. Enliven Therapeutics Inc shares valued at $278,646 were divested by the CHIEF SCIENTIFIC OFFICER at a price of $22.29 per share. As a result of the transaction, Lyssikatos Joseph P now holds 952,688 shares, worth roughly $18.31 million.
Goldman initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on June 16, 2025; the price target was $37. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. H.C. Wainwright began covering ELVN with “Buy” recommendation on September 09, 2024. Robert W. Baird started covering the stock on June 11, 2024. It rated ELVN as “an Outperform”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock jump 2.56% to $19.22. Over the last five days, the stock has lost -4.24%. Enliven Therapeutics Inc shares have fallen nearly -22.19% since the year began. Nevertheless, the stocks have fallen -14.58% over the past one year.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2025-07-15, dropping by -1.08 million shares to a total of 5.54 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 6.62 million shares. There was a decline of -19.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 09, 2024 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $34 price target.
